BioCentury | May 29, 2020
Management Tracks

Delaney takes over as Assembly’s CSO; plus NGM, TCR2, Amunix, Evox, Vor and more

...of finance for the global business unit of IQVia Holdings Inc. (NYSE:IQV). Regenerative medicines company Histogen Inc....
...Inc. TCR2 Therapeutics Inc. Evox Therapeutics Ltd. Vor Biopharma Inc. BrainStorm Cell Therapeutics Inc. Sierra Oncology Inc. Science 37 Inc. Amunix Pharmaceuticals Inc. Histogen Inc....
BioCentury | Jan 30, 2020
Financial News

Jan. 29 Financial Quick Takes: Black Diamond prices upsized IPO; plus Biohaven, Denali, Concert follow-ons, Lyra, Annovis, Histogen-Conatus and CellFE

...Down syndrome, AD and Parkinson’s disease. Histogen to trade on NASDAQ following reverse-merger with Conatus Histogen Inc....
...merge with Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) to create a publicly traded company that would advance Histogen’s...
...steatohepatitis candidate emricasan failed in a pair of Phase IIb studies in 2018 and 2019. Histogen...
BioCentury | Sep 19, 2019
Company News

Management tracks: CASI promotes Zhang to president; plus Five Prime, Black Diamond, Oyster Point, Enyo, X4, Nimbus and Canbridge

Cancer and generics company CASI Pharmaceuticals Inc. (NASDAQ:CASI) promoted Larry Zhang to president. He was president of the cancer and generics company's Chinese subsidiary CASI Pharmaceuticals (Beijing) Co. Ltd. Prior to joining CASI, Zhang was...
BioCentury | Jun 5, 2019
Company News

Management tracks: Settleman to lead Pfizer cancer R&D; plus Roivant, LabCorp and more

Pfizer Inc. (NYSE:PFE) hired Jeff Settleman as SVP and group head of oncology R&D, effective July 1. He was head of oncology research at Calico Life Sciences LLC (South San Francisco, Calif.) and prior to...
BioCentury | Apr 11, 2019
Company News

Ocugen to go public via Histogenics reverse merger

Ocugen will reverse merge with Histogenics to form a public company focused on discovering, developing and commercializing therapies for rare eye diseases. Ocugen Inc. (Malvern, Pa.) stockholders will own about 90% of the resulting company,...
BioCentury | Jan 28, 2019
Company News

Management tracks: Ironwood reveals board for new companies

...a series A round in 2017 that was co-led by Atlas Venture and F-Prime Capital. Histogen Inc....
...Richard Pascoe as chairman and CEO. He was CEO of Apricus Biosciences Inc. (NASDAQ:APRI). A Histogen...
BioCentury | Sep 21, 2018
Clinical News

Histogenics' NeoCart misses in Phase III for knee cartilage repair

Histogenics Corp. (NASDAQ:HSGX) said NeoCart missed the primary endpoint of improving pain and function at one year in a Phase III trial to repair knee cartilage damage. The company said the product narrowly missed the...
BioCentury | Jun 30, 2018
Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
BioCentury | Oct 13, 2017
Company News

Management tracks: Verastem, OxThera

Cancer company Verastem Inc. (NASDAQ:VSTM) named NgocDiep Le CMO. She was VP of immuno-oncology innovative medicines at the MedImmune LLC subsidiary of AstraZeneca plc (LSE:AZN; NYSE:AZN). Rare disease company OxThera AB (Stockholm, Sweden) named Bastian...
Items per page:
1 - 10 of 63
BioCentury | May 29, 2020
Management Tracks

Delaney takes over as Assembly’s CSO; plus NGM, TCR2, Amunix, Evox, Vor and more

...of finance for the global business unit of IQVia Holdings Inc. (NYSE:IQV). Regenerative medicines company Histogen Inc....
...Inc. TCR2 Therapeutics Inc. Evox Therapeutics Ltd. Vor Biopharma Inc. BrainStorm Cell Therapeutics Inc. Sierra Oncology Inc. Science 37 Inc. Amunix Pharmaceuticals Inc. Histogen Inc....
BioCentury | Jan 30, 2020
Financial News

Jan. 29 Financial Quick Takes: Black Diamond prices upsized IPO; plus Biohaven, Denali, Concert follow-ons, Lyra, Annovis, Histogen-Conatus and CellFE

...Down syndrome, AD and Parkinson’s disease. Histogen to trade on NASDAQ following reverse-merger with Conatus Histogen Inc....
...merge with Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) to create a publicly traded company that would advance Histogen’s...
...steatohepatitis candidate emricasan failed in a pair of Phase IIb studies in 2018 and 2019. Histogen...
BioCentury | Sep 19, 2019
Company News

Management tracks: CASI promotes Zhang to president; plus Five Prime, Black Diamond, Oyster Point, Enyo, X4, Nimbus and Canbridge

Cancer and generics company CASI Pharmaceuticals Inc. (NASDAQ:CASI) promoted Larry Zhang to president. He was president of the cancer and generics company's Chinese subsidiary CASI Pharmaceuticals (Beijing) Co. Ltd. Prior to joining CASI, Zhang was...
BioCentury | Jun 5, 2019
Company News

Management tracks: Settleman to lead Pfizer cancer R&D; plus Roivant, LabCorp and more

Pfizer Inc. (NYSE:PFE) hired Jeff Settleman as SVP and group head of oncology R&D, effective July 1. He was head of oncology research at Calico Life Sciences LLC (South San Francisco, Calif.) and prior to...
BioCentury | Apr 11, 2019
Company News

Ocugen to go public via Histogenics reverse merger

Ocugen will reverse merge with Histogenics to form a public company focused on discovering, developing and commercializing therapies for rare eye diseases. Ocugen Inc. (Malvern, Pa.) stockholders will own about 90% of the resulting company,...
BioCentury | Jan 28, 2019
Company News

Management tracks: Ironwood reveals board for new companies

...a series A round in 2017 that was co-led by Atlas Venture and F-Prime Capital. Histogen Inc....
...Richard Pascoe as chairman and CEO. He was CEO of Apricus Biosciences Inc. (NASDAQ:APRI). A Histogen...
BioCentury | Sep 21, 2018
Clinical News

Histogenics' NeoCart misses in Phase III for knee cartilage repair

Histogenics Corp. (NASDAQ:HSGX) said NeoCart missed the primary endpoint of improving pain and function at one year in a Phase III trial to repair knee cartilage damage. The company said the product narrowly missed the...
BioCentury | Jun 30, 2018
Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
BioCentury | Oct 13, 2017
Company News

Management tracks: Verastem, OxThera

Cancer company Verastem Inc. (NASDAQ:VSTM) named NgocDiep Le CMO. She was VP of immuno-oncology innovative medicines at the MedImmune LLC subsidiary of AstraZeneca plc (LSE:AZN; NYSE:AZN). Rare disease company OxThera AB (Stockholm, Sweden) named Bastian...
Items per page:
1 - 10 of 63